InvestmentAug 3, 2026, 07:21 AM
Cocrystal Pharma Raises $5M in Private Placement from OPKO Health
AI Summary
Cocrystal Pharma, Inc. announced a $5.0 million private placement with OPKO Health, Inc., a longtime investor and principal stockholder. The company sold 5,474,053 shares of common stock at $0.9134 per share. The net proceeds will be used to advance its preclinical and clinical drug candidate programs, including the norovirus Phase 1b trial, and for general corporate purposes and working capital.
Key Highlights
- Cocrystal Pharma raised $5.0 million in gross proceeds.
- The company sold 5,474,053 shares of common stock.
- The shares were sold at a purchase price of $0.9134 per share.
- OPKO Health, Inc., an accredited investor and principal stockholder, was the purchaser.
- Proceeds will fund preclinical and clinical drug candidate programs, and general corporate purposes.
- OPKO Health increased its position as Cocrystal advances its norovirus Phase 1b trial.
Price Impact
More from COCP